{"DataElement":{"publicId":"3370613","version":"1","preferredName":"Patient Head and Neck Malignant Neoplasm Clinical T Stage Clinical Trials Eligibility Criteria Stage","preferredDefinition":"the extent of a primary head and neck tumor determined prior to treatment based on evidence from clinical assessment parameters (e.g., physical exam, imaging, biopsy) following AJCC staging criteria.","longName":"3370504v1.0:3370610v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3370504","version":"1","preferredName":"Patient Head and Neck Malignant Neoplasm Clinical T Stage Clinical Trials Eligibility Criteria","preferredDefinition":"the extent of a primary head and neck tumor determined prior to treatment based on evidence from clinical assessment parameters (e.g., physical exam, imaging, biopsy) following AJCC staging criteria.","longName":"2177068v1.0:3370502v1.0","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3370502","version":"1","preferredName":"Head and Neck Malignant Neoplasm Clinical T Stage Clinical Trials Eligibility Criteria","preferredDefinition":"For oncology, area of the body generally construed to comprise base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:Having to do with the examination and treatment of patients.:One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3370502v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck","conceptCode":"C12418","definition":"For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical","conceptCode":"CL035092","definition":"Having to do with the examination and treatment of patients.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trials Eligibility Criteria","conceptCode":"CL008804","definition":"Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8155406-FA09-F579-E040-BB89AD4359AC","latestVersionIndicator":"Yes","beginDate":"2012-02-03","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-03","modifiedBy":"ONEDATA","dateModified":"2012-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8155406-FA1A-F579-E040-BB89AD4359AC","latestVersionIndicator":"Yes","beginDate":"2012-02-03","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to NRG for by script Fri Jan 24 11:30:54 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3370610","version":"1","preferredName":"Patient Head and Neck Malignant Neoplasm Clinical T Stage Clinical Trial Eligibility Criteria Stage","preferredDefinition":"The extent of a cancer within the head and neck for clinical T stage.","longName":"3370610v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T1","valueDescription":"T1 Stage Finding","ValueMeaning":{"publicId":"3687408","version":"1","preferredName":"T1 Stage Finding","longName":"3687408","preferredDefinition":"A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T1 TNM Finding","conceptCode":"C48720","definition":"A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5CA35AA-9F9B-FFA5-E040-BB89AD435F4C","latestVersionIndicator":"Yes","beginDate":"2013-02-15","endDate":null,"createdBy":"PATELV","dateCreated":"2013-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5CA35AA-9FB3-FFA5-E040-BB89AD435F4C","beginDate":"2013-02-15","endDate":null,"createdBy":"PATELV","dateCreated":"2013-02-15","modifiedBy":"ONEDATA","dateModified":"2013-02-15","deletedIndicator":"No"},{"value":"T2 -3","valueDescription":"T3 Stage Finding T2 Stage Finding","ValueMeaning":{"publicId":"3370611","version":"1","preferredName":"T3 Stage Finding T2 Stage Finding","longName":"3370611","preferredDefinition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.\r\n: A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T3 TNM Finding","conceptCode":"C48728","definition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T2 TNM Finding","conceptCode":"C48724","definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B84DB87E-EBFF-21D4-E040-BB89AD436BB9","latestVersionIndicator":"Yes","beginDate":"2012-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D5CA35AA-9FC8-FFA5-E040-BB89AD435F4C","beginDate":"2013-02-15","endDate":null,"createdBy":"PATELV","dateCreated":"2013-02-15","modifiedBy":"ONEDATA","dateModified":"2013-02-15","deletedIndicator":"No"},{"value":"T1-3","valueDescription":"T2 Stage Finding T3 Stage Finding T1 Stage Finding","ValueMeaning":{"publicId":"3380067","version":"1","preferredName":"T2 Stage Finding T3 Stage Finding T1 Stage Finding","longName":"3380067","preferredDefinition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.: A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.\r\n: A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T2 TNM Finding","conceptCode":"C48724","definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T3 TNM Finding","conceptCode":"C48728","definition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T1 TNM Finding","conceptCode":"C48720","definition":"A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B96A20CF-0528-EA09-E040-BB89AD4330C3","latestVersionIndicator":"Yes","beginDate":"2012-02-20","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B96A20CF-0541-EA09-E040-BB89AD4330C3","beginDate":"2012-02-06","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-20","modifiedBy":"ONEDATA","dateModified":"2012-02-20","deletedIndicator":"No"},{"value":"T4a","valueDescription":"T4a Stage Finding","ValueMeaning":{"publicId":"3370612","version":"1","preferredName":"T4a Stage Finding","longName":"3370612","preferredDefinition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4a TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the prostatic stroma, uterus, and vagina; for gastric cancer it refers to a primary tumor that invades the serosa (visceral peritoneum); for colorectal cancer it refers to a primary tumor that penetrates to the surface of the visceral peritoneum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T4a TNM Finding","conceptCode":"C48733","definition":"A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4a TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the prostatic stroma, uterus, and vagina; for gastric cancer it refers to a primary tumor that invades the serosa (visceral peritoneum); for colorectal cancer it refers to a primary tumor that penetrates to the surface of the visceral peritoneum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B84DB87E-EC22-21D4-E040-BB89AD436BB9","latestVersionIndicator":"Yes","beginDate":"2012-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B84DB87E-EC3B-21D4-E040-BB89AD436BB9","beginDate":"2012-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-02-06","modifiedBy":"ONEDATA","dateModified":"2012-02-06","deletedIndicator":"No"},{"value":"T1-2","valueDescription":"T1 Stage Finding T2 Stage Finding","ValueMeaning":{"publicId":"3812311","version":"1","preferredName":"T1 Stage Finding T2 Stage Finding","longName":"3812311","preferredDefinition":"A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.\r\n: A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T1 TNM Finding","conceptCode":"C48720","definition":"A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T2 TNM Finding","conceptCode":"C48724","definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1A2BE14-DBA8-00DD-E040-BB89AD432252","latestVersionIndicator":"Yes","beginDate":"2013-07-16","endDate":null,"createdBy":"RUETERJ","dateCreated":"2013-07-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1A2BE14-DBC1-00DD-E040-BB89AD432252","beginDate":"2013-07-16","endDate":null,"createdBy":"RUETERJ","dateCreated":"2013-07-16","modifiedBy":"ONEDATA","dateModified":"2013-07-16","deletedIndicator":"No"},{"value":"T3-4","valueDescription":"T3 Stage Finding T4 Stage Finding","ValueMeaning":{"publicId":"3812312","version":"1","preferredName":"T3 Stage Finding T4 Stage Finding","longName":"3812312","preferredDefinition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.\r\n: A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T3 TNM Finding","conceptCode":"C48728","definition":"A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T4 TNM Finding","conceptCode":"C48732","definition":"A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1A2BE14-DBCE-00DD-E040-BB89AD432252","latestVersionIndicator":"Yes","beginDate":"2013-07-16","endDate":null,"createdBy":"RUETERJ","dateCreated":"2013-07-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1A2BE14-DBE7-00DD-E040-BB89AD432252","beginDate":"2013-07-16","endDate":null,"createdBy":"RUETERJ","dateCreated":"2013-07-16","modifiedBy":"ONEDATA","dateModified":"2013-07-16","deletedIndicator":"No"},{"value":"T2","valueDescription":"T2 Stage Finding","ValueMeaning":{"publicId":"3905891","version":"1","preferredName":"T2 Stage Finding","longName":"3905891","preferredDefinition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T2 TNM Finding","conceptCode":"C48724","definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6D2DE7A-D155-19F1-E040-BB89AD433187","latestVersionIndicator":"Yes","beginDate":"2013-09-20","endDate":null,"createdBy":"PATELV","dateCreated":"2013-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6D2DE7A-D16E-19F1-E040-BB89AD433187","beginDate":"2013-09-20","endDate":null,"createdBy":"PATELV","dateCreated":"2013-09-20","modifiedBy":"ONEDATA","dateModified":"2013-09-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2428501","version":"1","preferredName":"Stage","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"053C2A34-089B-693F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-11","modifiedBy":"ONEDATA","dateModified":"2005-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B84DB87E-EBE6-21D4-E040-BB89AD436BB9","latestVersionIndicator":"Yes","beginDate":"2012-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-02-06","modifiedBy":"PATELV","dateModified":"2013-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4171051","version":"1","longName":"RTOG-1016","context":"NRG"},{"publicId":"4104935","version":"1","longName":"RTOG-1221","context":"NRG"},{"publicId":"4171052","version":"1","longName":"RTOG-0920","context":"NRG"}]}],"AlternateNames":[{"name":"PT_HN_MN_CLIN_T_ST","type":"Context Short Name","context":"CTEP"},{"name":"3370504v1.0:3370610v1.0","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Clinical T-Stage","type":"Preferred Question Text","description":"Clinical T-Stage","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Specify T stage","url":null,"context":"CTEP"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B84DB87E-EC45-21D4-E040-BB89AD436BB9","latestVersionIndicator":"Yes","beginDate":"2012-02-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-02-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}